Trending...
- Grammy award-winning Cuban-Canadian artist Alex Cuba releases his 11th studio album, "Indole"
- $73.6M Pipeline, $10M Crypto Play & Legal Firepower: Why Investors Are Watching Cycurion (N A S D A Q: CYCU) Like a Hawk
- California: Crime is down in San Francisco, key law enforcement partnerships yield successful results
Enabling reimbursement and expanded patient access—Effective January 2026
IRVINE, Calif. - Californer -- VESICA HEALTH®, INC., a precision diagnostics company improving the early detection and management of bladder cancer, today announced that the American Medical Association (AMA) has granted a Proprietary Laboratory Analysis (PLA) billing code for its AssureMDx™ test. The new code, effective January 2026, represents a critical de-risking milestone in Vesica Health's path to commercialization, establishing a recognized billing pathway that will enable reimbursement and support adoption of AssureMDx across the U.S. healthcare system. This achievement positions Vesica Health to accelerate revenue generation and deliver meaningful near-term value creation for our shareholders, while at the same time expanding access for patients.
"Securing a PLA code from the American Medical Association is a foundational milestone," said Christopher Thibodeau, Chief Executive Officer, Vesica Health. "It underscores the continued execution of our commercial strategy to expand access to AssureMDx, drive adoption across the healthcare system, and advance our mission to improve early detection and outcomes for patients, providers, and payers."
The AssureMDx PLA code (0613U) has been published in the AMA's Directory: https://www.ama-assn.org/practice-management/cpt/cpt-pla-codes
By establishing a clear reimbursement pathway, this milestone validates Vesica Health's position with payers, enables provider adoption, expands patient access, and demonstrates the company's ongoing commitment to all stakeholders.
More on The Californer
About AssureMDx™
AssureMDx is a proprietary, noninvasive urine-based DNA test clinically validated to improve the early detection of bladder cancer. The assay integrates six genomic and epigenetic biomarkers—DNA methylation of TWIST1, OTX1, and ONECUT2, and somatic mutations in FGFR3, HRAS, and TERT—to stratify hematuria patients for expedited urologic evaluation while safely ruling out those at very low risk.
Vesica Health's genes and technology have been reported in more than 26 peer-reviewed publications involving over 8,500 patients across detection, prognostic, and predictive applications. This body of evidence includes three prospective clinical validation studies evaluating the final six-gene configuration of the AssureMDx assay for early detection. In the largest multicenter study (n=838; van Kessel et al., Journal of Urology, 2020), AssureMDx demonstrated an overall sensitivity of 96%, a negative predictive value greater than 99%, and an AUC of 0.96 for bladder cancer detection. Answering the clinical community's call for earlier, more accurate detection, AssureMDx achieved a combined sensitivity of 95.9% for Stage 0 (Ta and Tis/CIS) and Stage I disease—underpinning its unique ability to identify patients at increased risk for bladder cancer at its earliest and most treatable stages.
AssureMDx has been recognized in the AUA Clinical Guidelines as a validated urine-based genomic test for the evaluation of patients with intermediate-risk microscopic hematuria, further reinforcing its clinical utility within the standard of care.
More on The Californer
About Vesica Health®, Inc.
Vesica Health is a privately held precision diagnostics company pioneering noninvasive solutions for the early detection and management of bladder cancer. Hematuria—blood in the urine—affects more than 17 million U.S. adults annually, yet only 12% are referred for urologic evaluation, resulting in an estimated 20,000 missed bladder cancer diagnoses each year.
Headquartered in Irvine, California, Vesica operates a CAP-accredited, CLIA-certified laboratory and holds worldwide commercialization rights for AssureMDx. The company is led by an experienced team with a proven track record in diagnostic development, clinical evidence generation, and commercial execution. In addition to its flagship assay, Vesica is advancing a pipeline that includes recurrence monitoring, prognostic, and predictive companion diagnostics.
Vesica Health is positioned to lead in the $6 billion bladder cancer diagnostics market, with a mission to improve survival and patient care through earlier detection, precision diagnostics, and expanded access to noninvasive solutions. Learn more at: www.vesicahealth.com.
For investment and partnership inquiries, or to learn more about AssureMDx, please contact Vesica Health Corporate Communications at: public.relations@vesicahealth.com
NOTE: The Vesica Health wordmarks and logos, including Vesica Health, and AssureMDx are trademarks or registered trademarks of Vesica Health, Inc. All other trademarks and service marks are the property of their respective owners.
"Securing a PLA code from the American Medical Association is a foundational milestone," said Christopher Thibodeau, Chief Executive Officer, Vesica Health. "It underscores the continued execution of our commercial strategy to expand access to AssureMDx, drive adoption across the healthcare system, and advance our mission to improve early detection and outcomes for patients, providers, and payers."
The AssureMDx PLA code (0613U) has been published in the AMA's Directory: https://www.ama-assn.org/practice-management/cpt/cpt-pla-codes
By establishing a clear reimbursement pathway, this milestone validates Vesica Health's position with payers, enables provider adoption, expands patient access, and demonstrates the company's ongoing commitment to all stakeholders.
More on The Californer
- Long Beach: City to Host Neighborhood Halloween Carnival at Silverado Park
- Altadena Mountain Rescue Team Recognized with 2025 ReadyCommunities Partnership National Service Award For Determination and Resilience
- Long Beach to Host Urban Forest Plan Kickoff Meeting
- Alander Lee Pulliam Jr. Declares His Bold Rise in Politics: A Mission Rooted in Service and Justice
- Alander Pulliam Unveils "Platform for Transformation" – A Bold Blueprint to Dismantle Oppres
About AssureMDx™
AssureMDx is a proprietary, noninvasive urine-based DNA test clinically validated to improve the early detection of bladder cancer. The assay integrates six genomic and epigenetic biomarkers—DNA methylation of TWIST1, OTX1, and ONECUT2, and somatic mutations in FGFR3, HRAS, and TERT—to stratify hematuria patients for expedited urologic evaluation while safely ruling out those at very low risk.
Vesica Health's genes and technology have been reported in more than 26 peer-reviewed publications involving over 8,500 patients across detection, prognostic, and predictive applications. This body of evidence includes three prospective clinical validation studies evaluating the final six-gene configuration of the AssureMDx assay for early detection. In the largest multicenter study (n=838; van Kessel et al., Journal of Urology, 2020), AssureMDx demonstrated an overall sensitivity of 96%, a negative predictive value greater than 99%, and an AUC of 0.96 for bladder cancer detection. Answering the clinical community's call for earlier, more accurate detection, AssureMDx achieved a combined sensitivity of 95.9% for Stage 0 (Ta and Tis/CIS) and Stage I disease—underpinning its unique ability to identify patients at increased risk for bladder cancer at its earliest and most treatable stages.
AssureMDx has been recognized in the AUA Clinical Guidelines as a validated urine-based genomic test for the evaluation of patients with intermediate-risk microscopic hematuria, further reinforcing its clinical utility within the standard of care.
More on The Californer
- KeysCaribbean Offers 20 Percent Off Seven-Night Stays For Private Home Collection Properties
- Advancing Circular Economy in Automotive ESD Packaging
- Playwrights Announced For The 2025 Bill And Judy Garrett Finish Line Commission
- Institute for Pet Health Sciences Names Boops Pets 2025 Product of the Year
- The Swig Company Presents:Re-Discovering Native America: Stories in Motion with The Red Road Project
About Vesica Health®, Inc.
Vesica Health is a privately held precision diagnostics company pioneering noninvasive solutions for the early detection and management of bladder cancer. Hematuria—blood in the urine—affects more than 17 million U.S. adults annually, yet only 12% are referred for urologic evaluation, resulting in an estimated 20,000 missed bladder cancer diagnoses each year.
Headquartered in Irvine, California, Vesica operates a CAP-accredited, CLIA-certified laboratory and holds worldwide commercialization rights for AssureMDx. The company is led by an experienced team with a proven track record in diagnostic development, clinical evidence generation, and commercial execution. In addition to its flagship assay, Vesica is advancing a pipeline that includes recurrence monitoring, prognostic, and predictive companion diagnostics.
Vesica Health is positioned to lead in the $6 billion bladder cancer diagnostics market, with a mission to improve survival and patient care through earlier detection, precision diagnostics, and expanded access to noninvasive solutions. Learn more at: www.vesicahealth.com.
For investment and partnership inquiries, or to learn more about AssureMDx, please contact Vesica Health Corporate Communications at: public.relations@vesicahealth.com
NOTE: The Vesica Health wordmarks and logos, including Vesica Health, and AssureMDx are trademarks or registered trademarks of Vesica Health, Inc. All other trademarks and service marks are the property of their respective owners.
Source: Vesica Health, Inc.
0 Comments
Latest on The Californer
- Suicide Commando Ignites DNA Lounge in a Night of Industrial Euphoria
- Tami Goveia Enters FabOver40, Inspiring Hollywood Legacy for Breast Cancer Cause
- Trump shutdown could soon halt food support for millions in California; CalFresh cards face possibility of no new funds in November
- Why Authentic Communication Will Outperform AI in the Future of Sales
- California: Governor Newsom to the Supreme Court: do not let Trump use the military against American communities
- Luxury Hospitality Advisors Launches Realtor Training Based on Five Star Hotel Service Training
- Swidget Launches Luminance™ to Help Schools Achieve Alyssa's Law Compliance
- Farther's Michael Lee Named One of InvestmentNews' Rising Stars of 2025
- Growing Demand for EVA Mats Signals Shift in Car Interior Market
- 4th Annual Holidays In The Village, A European Marketplace
- Moorpark College Named 2025 Pathway Champion for Driving Equity in Transfer Success
- MDRN MUSE Expands Insurance Network Coverage to Include Delta Dental & Cigna
- Chera TV: The Female-Led Platform Redefining Hollywood's Next Era of Storytelling
- California Student Aid Commission Launches 2026-27 Statewide Financial Aid Cycle at Ventura College
- California: Governor Newsom supports workers as Trump's shutdown hurts the economy
- California strengthens its pipeline for good-paying jobs, providing $25 million to train more than 22,000 workers through apprenticeship programs
- Why Voting "No on Prop 50" Makes Sense
- Hollywood In Pixels Celebrates the 8th Annual Silver Pixel Awards and Announces 2025 Campaign Pixel Winners Los Angeles, CA — Oct
- While the Trump administration cuts programs to fight hate crimes, California is taking action every day
- The AI Journal Publishes Groundbreaking Article